An interventional study of Portal Message with Reminder Text Messages and Text Message with Reminder Text Messages in Lung Cancer, sponsored by Wake Forest University Health Sciences. Recruiting at 1 site in United States. Open to participants aged 50 Years to 77 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Lung Neoplasms by Wake Forest University Health Sciences — 3 open to participants now, 6 under way, none of them phase 3. Lung Neoplasms · Wake Forest University Health Sciences.
Among the 36 studies in Lung Neoplasms by Wake Forest University Health Sciences, this one has the largest planned enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2026, is one of 14 with no phase, and was the 36th registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →3 of the 36 studies in Lung Neoplasms by Wake Forest University Health Sciences are open now, in 1 country. Recruiting first, the newest first:
Wake Forest University Health Sciences · Sites in United States
Ages 40–54 · Healthy volunteers
Wake Forest University Health Sciences · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 50 Years to 77 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 3
First in 1998; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 27,000 is above the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Median enrollment 46 across the 31 interventional studies, 55 across the 5 observational. Of the 27 that completed or were terminated, 13 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
Wake Forest University Health Sciences is the lead sponsor of 1,353 studies on the registry; 199 are open to participants now.
Of its 332 completed or terminated interventional studies of FDA-regulated products, 251 (76%) have results posted.
3 of the studies in Lung Neoplasms by Wake Forest University Health Sciences that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06383988Wake Forest University Health SciencesA Web-based Program to Help Caregivers of Lung Patients Learn About Available Supportive Care Resources | 2026-12-30 |
| NCT07322367Wake Forest University Health SciencesA Mobile Patient Health Technology Intervention for Improving Lung Cancer Screening Rates in Eligible High Risk Patients | 2027-01 |
| NCT07282444Wake Forest University Health SciencesA New Way to Share Radiation Therapy Plans Between Doctors, CORRECT Trial | 2027-11-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies in Lung Neoplasms by Wake Forest University Health Sciences, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the real-world effectiveness and implementation strategies for mPATH-Lung, investigators propose a pragmatic, randomized controlled trial across an academic Learning Health System. The trial will contrast several approaches to participant outreach and will specifically target engaging fully powered cohorts of racial/ethnic minorities and rural residents.
Primary Objective: Evaluate the real-world effectiveness of mPATH-Lung in increasing lung cancer screening rates across diverse populations.
Secondary Objectives
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Eligible patients will:
Exclusion Criteria:
The following patients will be excluded:
electronic health record Prior history of lung cancer electronic health record Chest CT within the last 12 months electronic health record Those meeting the HEDIS COL-E measure exclusion criteria based on significant comorbidities and/or frailty.
Patient portal message first followed by up to 3 reminder text messages.
Other: Portal Message with Reminder Text Messages
Text message only with up to 3 reminder text messages.
Other: Text Message with Reminder Text Messages
Portal message only with no reminder messages.
Other: Portal message only
Patients receive usual care.
Other: Usual Care
If the participant has an upcoming scheduled appointment, they will receive a reminder text message 5 days after initial portal message, a final reminder text message a day before their scheduled appointment, and potentially an 'in progress' text message reminder if they start the mPATH-Lung program but do not complete it. If the participant does not have an upcoming scheduled appointment, they will receive a reminder text message 5 days after initial portal message, the final reminder message 8 days after the initial message, and potentially an 'in progress' text message reminder.
If the participant has an upcoming scheduled appointment, they will receive a reminder text message 5 days after initial message, a final reminder text message a day before their scheduled appointment, and potentially an 'in progress' text message reminder. If the participant does not have an upcoming scheduled appointment, they will receive a reminder text message 5 days after initial message, the final reminder message 8 days after the initial message, and potentially an 'in progress' text message reminder.
Participant will only receive portal message with no reminder text messages.
Standard of care
Number of Participants to Complete Lung Screening CT - Primary Effectiveness
Completion of the lung screening CT by participants.
Time frame: 90 days
Number of Participants with Eligibility for Lung Screening
Reach of the mPATH-Lung platform, defined as the participants who determine their eligibility for lung screening within the mPATH-Lung program within 90 days of the first invitation. Investigators will determine reach overall, within subgroups, and within study arms.
Time frame: 90 days
Number of Requests for Lung Screening
Requests for lung screening within the mPATH-Lung program
Time frame: 90 days
Number of Orders for Lung Screening CT Scans
Orders for lung screening CT scans for participants in study arms
Time frame: Within 90 days of randomization
Amount of Revenue Generated
Revenue (costs) generated from lung cancer screening and follow-up care.
Time frame: 12 months following completion of screenings
Number of Participants that Represent Over-screening
Among patients with newly diagnosed lung cancer by lung screening, the participants that represent over-screening, defined as a patient being deemed too ill for potentially curative surgery on blinded chart review.
Time frame: 90 days
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Jan 2027, 10 months after the start.
Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 10 months is below that.
Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wake Forest University Health Sciences →